According to a report from Market Research Store, the worldwide regenerative medicine market is expected to reach $24.7 billion by 2017. Regenerative medicine in the orthopedic market alone is expected to reach $10.3 billion by 2017, the report notes.
Indeed, the bullish outlook for regenerative medicine does not come as a surprise. According to ISTO Technologies Inc., regenerative medicine is not only gaining in pedigree but also in market value. ISTO notes that the money in the sector continues to grow.
Citing a report from MarketResearchReports, ISTO notes that the global regenerative medicine market will be worth around $67.6 billion by 2020, which would represent an increase of around fourfold from the levels in 2013. The market is expected to grow at a CAGR of 23.2% until 2020, which is very impressive by any standards.
According to MarketResearchReports, biologics constitute the largest segment value followed closely by cell and gene therapy. The small molecules and biologics segment is forecast to grow at a CAGR of 18.9% between 2014 and 2020, according to the research report. Gene therapy, meanwhile, is expected to grow at a CAGR of 28.6% during the forecast period.
The robust outlook for regenerative medicine is reflected in Bioheart Inc.’s (OTCQB:BHRT) performance for the first half of 2015. Based in Sunrise, Florida, BHRT is committed to the development of effective cell technologies to treat cardiovascular diseases. The company is engaged in the discovery, development, and commercialization of cell-based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.
This morning, BHRT reported that its total asset position increased 35.6% from December 31, 2014 to the end of the first half of this year. The company also reduced its current liabilities by 26.4%. Product and services revenue for the six-month period rose 8.5% on a year-over-year basis. BHRT reported net income of $886,594 for the second quarter of 2015. On a per share basis, net income for the quarter was $0.001.
Mike Tomas, President and CEO of Bioheart, said that as reflected by first-half and second-quarter 2015 financial performance improvements, BHRT continues to improve its top-line revenue performance and balance sheet positions. Tomas said that as the company resolves long-standing legacy matters, investor interest in its growth and turnaround plan continues to improve.
Investors seem to be giving the recent financials the thumbs up with shares of BHRT trading up over 11% in mid-day trading on the back of the news.
